[
  {
    "date": "2024-03-30",
    "symbol": "NBIO",
    "period": "FY",
    "entityregistrantname": "NASCENT BIOTECH INC.",
    "entitycentralindexkey": 1622057,
    "documenttype": "10-K",
    "amendmentflag": "false",
    "entityvoluntaryfilers": "No",
    "currentfiscalyearenddate": "--03-31",
    "entitywellknownseasonedissuer": "No",
    "entitysmallbusiness": "true",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entitycurrentreportingstatus": "Yes",
    "documentperiodenddate": "2024-03-31",
    "entityfilercategory": "Non-accelerated Filer",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2024,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "entityfilenumber": "000-55299",
    "entityincorporationstatecountrycode": "NV",
    "entitytaxidentificationnumber": "46-5001940",
    "entityaddressaddressline1": "631 US Hwy 1 Suite 407",
    "entityaddressaddressline2": "Suite 407",
    "entityaddresscityortown": "N Palm Beach",
    "entityaddressstateorprovince": "FL",
    "entityaddresspostalzipcode": 33408,
    "cityareacode": 612,
    "localphonenumber": "961-5656",
    "entityinteractivedatacurrent": "Yes",
    "auditorname": "Fruci & Associates II, PLLC",
    "auditorfirmid": 5525,
    "auditorlocation": "Spokane, Washington",
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 372120,
    "prepaidexpensecurrent": 180000,
    "assetscurrent": 552120,
    "assets": 552120,
    "accountspayableandaccruedliabilitiescurrent": 686294,
    "convertiblenotespayablecurrent": 122500,
    "liabilitiescurrent": 808794,
    "liabilities": 808794,
    "commonstockvalue": 170594,
    "additionalpaidincapital": 23833189,
    "retainedearningsaccumulateddeficit": -24260457,
    "stockholdersequity": -256674,
    "liabilitiesandstockholdersequity": 552120,
    "preferredstockparorstatedvaluepershare": 0.001,
    "preferredstocksharesauthorized": 50000000,
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": 500000000,
    "commonstocksharesissued": 170594165,
    "commonstocksharesoutstanding": 170594165,
    "professionalfees": 1303342,
    "generalandadministrativeexpense": 403589,
    "expensesrelatedtoclinicaltrials": 92466,
    "manufacturingcosts": 319507,
    "researchanddevelopmentexpense": 110975,
    "operatingexpenses": 2229879,
    "operatingincomeloss": -2229879,
    "interestincomeother": 5265,
    "interestexpense": 385236,
    "gainslossesonextinguishmentofdebt": 50000,
    "changeinfairvalueofderivativeliabilities": 472168,
    "othernonoperatingincomeexpense": 142197,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -2087682,
    "netincomeloss": -2087682,
    "netincomelosspersharebasicanddiluted": -0.01,
    "weightedaveragenumberofsharesoutstandingbasicanddiluted": 155744233,
    "sharesissued": 170594165,
    "stockissuedduringperiodsharesissuedforservices": 386250,
    "stockissuedduringperiodvalueissuedforservices": 386,
    "commonstockissuedtorelatedpartiesforserviceshares": 7186387,
    "commonstockissuedtorelatedpartiesforserviceamount": 7187,
    "stockissuedduringperiodvaluestockoptionsexercisednetoftaxbenefitexpense": 48000,
    "stockissuedduringperiodsharesnewissues": 19970000,
    "stockissuedduringperiodvaluenewissues": 19970,
    "conversionofstocksharesconverted1": 500000,
    "conversionofstockamountconverted1": 50000,
    "commonstockissuedforconversionofdebtshares": 10787180,
    "commonstockissuedforconversionofdebtamount": 10787,
    "changeinderivativeatconversion": 191258,
    "downroundofwarrants": 550000,
    "profitloss": -2087682,
    "sharebasedcompensation": 60850,
    "sharebasedcompensationrelatedparties": 773241,
    "gainlossinfairvalueofderivativeliability": 472168,
    "amortizationoffinancingcostsanddiscounts": 377909,
    "lossonnotes": 50000,
    "stockoptionplanexpense": 48000,
    "increasedecreaseinprepaidexpense": 97184,
    "increasedecreaseinaccountspayableandaccruedliabilities": 260968,
    "netcashprovidedbyusedinoperatingactivities": -1186066,
    "proceedsfromissuanceofcommonstock": 1561000,
    "proceedsfromconvertibledebt": 225000,
    "repaymentsofconvertibledebt": 400000,
    "netcashprovidedbyusedinfinancingactivities": 1386000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": 199934,
    "issuanceofcommonstockfordebtconversion": 673267,
    "changeinfairvalueatinitialissuanceandconversion": -191258,
    "changeinderivative": -472168,
    "workingcapitaldeficitamount": -256674,
    "fiscalyearannualizedcompensationbeingpaid": 252000,
    "nondilutivesharespercentage": 0.12,
    "initialshareawardsundercontracts": 1028910,
    "additionalsharesearnedtomaintainownershippercentage": 14712669,
    "totalsharesearned": 15741579,
    "officersanddirectorsemploymentagreementtermsdescription": "Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company.",
    "commonstocksissuedduringperiodissuedforservices": 7186385,
    "cashpaid": 180000,
    "commonstocksissuedduringperiodvalueissuedforservices": 773241,
    "stockissuedduringperiodsharesconversionofunits": 10787180,
    "commonstockissuedforserviceshares": 386250,
    "commonstockissuedforserviceamount": 35850,
    "stockissuedduringperiodvalueconversionofunits": 684054,
    "conversionsofstocksharesconverted1": 500000,
    "commonstocksharesvalueforcashamount": 1561000,
    "commonstocksharesvalueforcashshares": 19970000,
    "stockissuedduringperiodsharesother": 886250,
    "stockissuedduringperiodvalueother": 60850,
    "treasurystockretiredparvaluemethodamount": 773241,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsbeginning": 1430000,
    "optionexercised": -500000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsending": 930000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepricebeginning3": 0.28,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsweightedaverageexercisepriceending": 0.34,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P3Y9M22D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermending": "P2Y9M21D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingnumberbeginning": 930000,
    "sharebasedcompensationarrangementoutstandingnumberending": 930000,
    "commonstockexercisableterm": "P10Y",
    "optionsvesteddescription": "The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted",
    "investmentoptionsexerciseprice": 0.3,
    "optionawardsexpences": 48000,
    "numberofinstallmentsvest": 5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsgranted": 40000,
    "noncashorpartnoncashacquisitionnoncashfinancialorequityinstrumentconsiderationoptionsissued1": 40000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.37,
    "fairvalueofoption": 9991,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingbeginning": 1000000,
    "sharebasedcompensationarrangementgrantsinperiodgross": 250000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingnumberending1": 1250000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepricebeginning": 0.6,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice1": 0.6,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepriceending1": 0.16,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm1": "P1Y5M30D",
    "weightedaverageremainingcontractlifegrantedone": "P2Y9M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermending1": "P11M12D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsaggregateintrinsicvalueoutstandingending1": 134500,
    "classofwarrantorrightoutstanding": 1250000,
    "deemeddividenddownround": 550000,
    "debtinstrumentconvertibleconversionprice1": 0.05,
    "deferredtaxassetsoperatinglosscarryforwards": 1238858,
    "deferredtaxassetsvaluationallowance": 1238858,
    "operatinglosscarryforwards": 14783216,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "descriptionrelatedtopaymentofdebenture": "the Company paid the debenture owner $50,000 on August 24, 2023. The terms of the agreement requires principal payments of $50,000, which was made before September 30, 2023, $50,000 to be paid on or before October 31, 2023 and the balance of $250,000 on or before December 31, 2023",
    "debtinstrumentconvertiblebeneficialconversionfeature": 470000,
    "accruedbonusescurrent": 125000,
    "issuanceofaggregatesharesofcommonstockvalue": 673267,
    "debtconversiondescription": "Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Companyâ€™s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.035,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P1Y",
    "commonunitissued": 871323,
    "commonstockretiringnotevalue": 50000,
    "conversionofconvertiblenoteinterest": 22795,
    "exercisepriceofwarrant": 0.6,
    "debtinstrumentissuanceamountofconvertibledebenture": 250000,
    "malpracticelosscontingencydiscountrate": 0.1,
    "debtinstrumentmaturitydate": "2024-05-30",
    "commonstockconvertibleconversionpriceincrease": 0.1,
    "debtconversionconvertedinstrumentrate": 0.06,
    "agreementdescription": "Under the terms of the agreement the Company received $250,000 upon signing of the agreement plus $750,000 when the phase 1 clinical trial started in March 2021. In addition, the Company received $750,000 upon the initial patient enrolled at the dosage level of 8.0 mg/kg. Further payment of $2,500,000 were to be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials was to begin",
    "indefinitelivedlicenseagreements": 1750000,
    "issuanceoflicenseagreement": 5000000,
    "royaltyrate": 0.09,
    "royaltyratenetsalesterm": "P20Y"
  },
  {
    "date": "2023-03-30",
    "symbol": "NBIO",
    "period": "FY",
    "entityregistrantname": "NASCENT BIOTECH INC.",
    "entitycentralindexkey": 1622057,
    "documenttype": "10-K",
    "amendmentflag": "false",
    "entityvoluntaryfilers": "No",
    "currentfiscalyearenddate": "--03-31",
    "entitywellknownseasonedissuer": "No",
    "entitysmallbusiness": "true",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entitycurrentreportingstatus": "Yes",
    "documentperiodenddate": "March 31, 2023",
    "entityfilercategory": "Non-accelerated Filer",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2023,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityfilenumber": "000-55299",
    "entityincorporationstatecountrycode": "Nevada",
    "entitytaxidentificationnumber": "46-5001940",
    "entityinteractivedatacurrent": "Yes",
    "entityaddressaddressline1": "631 US Hwy 1 Suite 407",
    "entityaddressstateorprovince": "FL",
    "entityaddresspostalzipcode": 33408,
    "cityareacode": 612,
    "localphonenumber": "961-5656",
    "entityaddresscityortown": "N Palm Beach",
    "auditorfirmid": 5525,
    "auditorlocation": "Spokane, Washington",
    "auditorname": "Fruci & Associates II, PLLC",
    "cash": 172186,
    "prepaidexpenseandotherassetscurrent": 82816,
    "assetscurrent": 255002,
    "assets": 255002,
    "accountspayableandaccruedliabilitiescurrent": 498122,
    "convertiblenotespayablecurrent": 389591,
    "derivativeliabilities": 663426,
    "liabilitiescurrent": "null",
    "liabilities": "null",
    "commonstockvalue": 131764,
    "additionalpaidincapital": "null",
    "retainedearningsaccumulateddeficit": "-null",
    "stockholdersequity": "-null",
    "liabilitiesandstockholdersequity": 255002,
    "preferredstockparorstatedvaluepershare": 0.001,
    "preferredstocksharesauthorized": "null",
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": "null",
    "commonstocksharesissued": "null",
    "commonstocksharesoutstanding": 131764348,
    "professionalfees": "null",
    "generalandadministrativeexpense": 389767,
    "expensesrelatedtoclinicaltrials": 383688,
    "researchanddevelopmentexpense": 270529,
    "operatingexpenses": "null",
    "operatingincomeloss": "-null",
    "interestincomeoperating": 274,
    "interestexpense": "null",
    "financecostsexpenses": -5124,
    "gainslossesonextinguishmentofdebt": 28000,
    "originalinterestdebtdiscountamount": -156229,
    "gainlossonsaleofderivatives": "null",
    "othernonoperatingincomeexpense": -645212,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": "-null",
    "netincomeloss": "-null",
    "netincomelosspersharebasicanddiluted": -0.02,
    "weightedaveragenumberofsharesoutstandingbasicanddiluted": "null",
    "sharesissued": "null",
    "commonstockissuedforserviceshares": "null",
    "commonstockissuedforconversionofpayablesamount": 60000,
    "commonstockissuedforconversionofpayablesshares": 37700,
    "commonstockissuedforconversionofpayablesotheramount": 9275,
    "commonstockissuedtorelatedpartyforserviceshares": "null",
    "commonstockissuedtorelatedpartyforserviceamount": 624320,
    "commonstockissuedfortheconversionofdebtshares": "null",
    "commonstockissuedfortheconversionofdebtamount": "null",
    "commonstockissuedfortheconversionofwarrantsshares": "null",
    "commonstockissuedfortheconversionofwarrantsamount": 208000,
    "warrantsissuedwithconvertiblenotes": 178739,
    "stockoptionplanexpense": 72000,
    "profitloss": "null",
    "sharebasedcompensation": 60000,
    "stockbasedcompensationrelatedparties": -624320,
    "gainlossonforeigncurrencyfairvaluehedgederivatives": "null",
    "amortizationoffinancingcostsanddiscounts": "null",
    "lossonnotes": -286265,
    "stockoptionsplanexpense": 72000,
    "increasedecreaseinprepaidexpense": 71816,
    "increasedecreaseinaccountspayableandaccruedliabilities": -245519,
    "netcashprovidedbyusedinoperatingactivities": "-null",
    "proceedsfromconvertibledebt": "null",
    "commonstockissuedfortheexerciseofwarrants": 208000,
    "repaymentsofconvertibledebt": 275000,
    "netcashprovidedbyusedinfinancingactivities": "null",
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": 77772,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 172186,
    "interestpaidnet": 11135,
    "commonstockissuedforconvertibledebt": "null",
    "commonstockissuedforaccountspayable": 9275,
    "initialdiscountfromderivatives": 178739,
    "derivativefairvalueofderivativeliability": 663426,
    "changeinfairvalueatinitialissuanceandconversion": 178739,
    "changeinfairvalueofthederivative": "null",
    "changeinfairvalueatconversion": -570099,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 1,
    "workingcapitaldeficit": "-null",
    "cumulativeearningsdeficit": "-null",
    "fiscalyearannualizedcompensationbeingpaid": 452000,
    "nondilutivesharespercentage": 0.18,
    "initialshareawardsundercontracts": "null",
    "additionalsharesearnedtomaintainownershippercentage": "null",
    "totalsharesearned": "null",
    "cashpaid": 252000,
    "stockissuedduringperiodvalueissuedforservices": "null",
    "stockissuedduringperiodsharesissuedforservices": "null",
    "accruedcompensationamount": 20000,
    "officersanddirectorsemploymentagreementtermsdescription": "Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company",
    "bonusamount": 170000,
    "commonstocksharesvalueforservicesamount": 9275,
    "commonstocksharesvalueforclinicalconsultingamount": 60000,
    "commonstockdividendsshares": 37700,
    "commonstocksharesvaluethreerelatedservice": 624320,
    "debtconversiondescription": "Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Companyâ€™s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value",
    "commonstockshares": "null",
    "conversionofcommonstockintowarrant": "null",
    "warrantvalueofreceivedincash": 208000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsbeginning": 930000,
    "outstandingoptiongranted": 500000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsending": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepricebeginning3": 0.34,
    "weightedaverageexercisepricegranted": 0.18,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsweightedaverageexercisepriceending": 0.28,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P3Y9M18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaveragegranted": 4.75,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermending": 3.81,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingnumberbeginning": 930000,
    "sharebasedcompensationarrangementoutstandingnumberending": 930000,
    "unrecognizedfuturebalancevestingtermoption": 26219,
    "commonstockexercisableterm": 10,
    "optionsvesteddescription": "The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted.",
    "investmentoptionsexerciseprice": 0.25,
    "optionawardsexpences": 72000,
    "numberofinstallmentsvest": 5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsgranted": 40000,
    "noncashorpartnoncashacquisitionnoncashfinancialorequityinstrumentconsiderationoptionsissued1": 40000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.37,
    "fairvalueofoption": 9991,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingbeginning": 3700000,
    "sharebasedcompensationarrangementgrantsinperiodgross": "null",
    "stockissuedduringperiodexercised": "-null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingnumberending1": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepricebeginning": 0.04,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice1": 0.6,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepriceending1": 0.6,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm1": 1.35,
    "weightedaverageremainingcontractlifegrantedone": 1.75,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermending1": 1.5,
    "warrantoutstanding": "null",
    "warrantconvertedintocommonstock": 500000,
    "warrantconverted": 500000,
    "deferredtaxassetsoperatinglosscarryforwards": "null",
    "deferredtaxassetsvaluationallowance": "null",
    "operatinglosscarryforwards": "null",
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "stockissuedduringperiodvalueconversionofunits": 823975,
    "convertiblenotesconversion": 23975,
    "interestonnotes": 800000,
    "notespayable": 200000,
    "accruedbonusescurrent": 700000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0347,
    "stockissuedduringperiodsharesconversionofunits": "null",
    "exercisepriceofwarrant": 0.6,
    "agreementdescription": "Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company received $750,000 upon the initial patient enrolled at the dosage level of 8.0 mg/kg. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin.",
    "receivablesnetcurrent": "null",
    "issuanceoflicenseagreement": "null",
    "royaltyrate": 0.09,
    "netsales": 20,
    "annualmaintenance": 19300
  },
  {
    "date": "2022-03-30",
    "symbol": "NBIO",
    "period": "FY",
    "entityregistrantname": "NASCENT BIOTECH INC.",
    "entitycentralindexkey": 1622057,
    "documenttype": "10-K",
    "amendmentflag": "false",
    "entityvoluntaryfilers": "No",
    "currentfiscalyearenddate": "--03-31",
    "entitywellknownseasonedissuer": "No",
    "entitysmallbusiness": "true",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entitycurrentreportingstatus": "Yes",
    "documentperiodenddate": "March 31, 2022",
    "entityfilercategory": "Non-accelerated Filer",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2022,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityfilenumber": "000-55299",
    "entityincorporationstatecountrycode": "Nevada",
    "entitytaxidentificationnumber": "46-5001940",
    "entityinteractivedatacurrent": "Yes",
    "entityaddressaddressline1": "623 17th Street Suite 4",
    "entityaddresscityortown": "Vero Beach",
    "entityaddresspostalzipcode": 32960,
    "cityareacode": 612,
    "localphonenumber": "961-5656",
    "entityaddressstateorprovince": "FL",
    "auditorname": "Spokane",
    "auditorlocation": "Washington",
    "auditorfirmid": 5525,
    "cash": 94414,
    "prepaidexpenseandotherassetscurrent": 11000,
    "assetscurrent": 105414,
    "assets": 105414,
    "accountspayableandaccruedliabilitiescurrent": 776890,
    "liabilitiescurrent": 776890,
    "liabilities": 776890,
    "commonstockvalue": 111313,
    "additionalpaidincapital": "null",
    "retainedearningsaccumulateddeficit": "-null",
    "stockholdersequity": "-null",
    "liabilitiesandstockholdersequity": 105414,
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": "null",
    "commonstocksharesissued": "null",
    "commonstocksharesoutstanding": 111313175,
    "preferredstockparorstatedvaluepershare": 0.001,
    "preferredstocksharesauthorized": "null",
    "revenues": "null",
    "professionalfees": 12000,
    "generalandadministrativeexpense": 379424,
    "clinicaltrials": 332289,
    "researchanddevelopmentexpense": 197406,
    "operatingexpenses": "null",
    "operatingincomeloss": -457052,
    "interestincomeoperating": 12,
    "interestexpense": 48044,
    "financecosts": -151150,
    "gainslossesonextinguishmentofdebt1": 5000,
    "amortizationofdebtdiscountpremium": -287979,
    "gainlossonsaleofderivatives": 468823,
    "othernonoperatingincomeexpense": -13338,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -470390,
    "netincomeloss": -470390,
    "weightedaveragenumberofsharesoutstandingbasicanddiluted": "null",
    "sharesissued": "null",
    "stockissuedduringperiodvalueissuedforservices": 110835,
    "commonstockissuedfortheconversionofpreferredsharesshares": "null",
    "commonstockissuedfortheconversionofpreferredsharesamount": -1914,
    "commonstockforserviceshares": 50000,
    "commonstockforserviceamount": 5250,
    "commonstocktorelatedpartiesforserviceshares": "null",
    "commonstocktorelatedpartiesforserviceamount": 110836,
    "commonstocktorelatedpartiesforconversionofpayablesshares": "null",
    "commonstocktorelatedpartiesforconversionofpayablesamount": 128333,
    "commonstockforconversionofpayablesshares": 540000,
    "commonstockforconversionofpayablesamount": 27000,
    "netlossincome": 470390,
    "sharebasedcompensation": 5250,
    "stockissuedduringperiodvaluesharebasedcompensationgross": 110835,
    "gainlossonforeigncurrencyfairvaluehedgederivatives": 468823,
    "debtconversionoriginaldebtamount1": 325431,
    "increasedecreaseinaccountsreceivable": 750000,
    "increasedecreaseinprepaidexpense": 11000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 167060,
    "increasedecreaseinduetorelatedparties": 5116,
    "netcashprovidedbyusedinoperatingactivities": 413479,
    "proceedsfromconvertibledebt": 200000,
    "repaymentofconvertiblenotes": 520500,
    "netcashprovidedbyusedinfinancingactivities": -320500,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": 92979,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 94414,
    "interestpaidnet": 30027,
    "increasedecreaseinnotespayablerelatedparties": 128333,
    "stockissuedduringperiodsharesperiodincreasedecrease": 1968,
    "conversionofstockamountissued1": 5250,
    "changeinfairvalueatinitialissuance": 166667,
    "changeinfairvalueofthederivative": -468823,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 5,
    "workingcapitaldeficit": -671477,
    "fiscalyearannualizedcompensationbeingpaid": 452000,
    "nondilutivesharespercentage": 0.18,
    "initialshareawardsundercontracts": "null",
    "additionalsharesearnedtomaintainownershippercentage": "null",
    "totalsharesearned": "null",
    "cashpaid": 221500,
    "stockissuedduringperiodsharesissuedforservices": "null",
    "accountspayableothercurrent": 27000,
    "accountpayableshares": 540000,
    "accruedcompensationamount": 20000,
    "accruedbonusescurrent": 30500,
    "convertiblepreferredstocksharesissueduponconversion": 54130,
    "accruedfeesconvertedamountintoshares": "null",
    "officersanddirectorsemploymentagreementtermsdescription": "Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company.",
    "bonusamount": 170000,
    "commonstockpricepershare": 1,
    "conversionofstocksharesissued1": 50000,
    "treasurystockretiredparvaluemethodamount": 27000,
    "commonstockdividendsshares": 540000,
    "conversionofstocksharesconverted1": "null",
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsbeginning": "null",
    "outstandingoptionforfeited": -475000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsending": 930000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepricebeginning3": 0.34,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsweightedaverageexercisepriceending": 0.34,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": 5.8,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermending": 4.8,
    "stockissuedduringperiodsharessharebasedcompensationforfeited": 475000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingnumberbeginning": 1405000,
    "sharebasedcompensationarrangementoutstandingnumberending": 930000,
    "vestpercentageatgrant": 0.2,
    "commonstockexercisableterm": 10,
    "optionsvesteddescription": "The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted.",
    "investmentoptionsexerciseprice": 0.25,
    "numberofinstallmentsvest": 5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsgranted": 30000,
    "noncashorpartnoncashacquisitionnoncashfinancialorequityinstrumentconsiderationoptionsissued1": 40000,
    "fairvalueofoption": 9991,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingbeginning": 3700000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingnumberending1": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepricebeginning": 0.04,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepriceending1": 0.04,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm1": "P1Y4M6D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermending1": 0.35,
    "sharesoutstanding": 3700000,
    "deferredtaxassetsoperatinglosscarryforwards": 319880,
    "deferredtaxassetsvaluationallowance": 319880,
    "operatinglosscarryforwards": "null",
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "agreementdescription": "Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company received $750,000 upon the initial patient enrolled at the dosage level of 8.0 mg/kg. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin.",
    "issuanceoflicenseagreement": "null",
    "royaltyrate": 0.09,
    "netsales": 20,
    "accruedfeesandotherrevenuereceivable": 270000,
    "otheraccruedliabilitiescurrent": 28000
  },
  {
    "date": "2021-03-30",
    "symbol": "NBIO",
    "period": "FY",
    "entityregistrantname": "Nascent Biotech Inc.",
    "entitycentralindexkey": 1622057,
    "documenttype": "10-K",
    "amendmentflag": "false",
    "entityvoluntaryfilers": "No",
    "currentfiscalyearenddate": "--03-31",
    "entitywellknownseasonedissuer": "No",
    "entitysmallbusiness": "true",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entitycurrentreportingstatus": "Yes",
    "documentperiodenddate": "2021-03-31",
    "entityfilercategory": "Non-accelerated Filer",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2021,
    "entityextransitionperiod": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityinteractivedatacurrent": "Yes",
    "cash": 1435,
    "accountsreceivablenetcurrent": 750000,
    "assetscurrent": 751435,
    "assets": 751435,
    "accountspayableandaccruedliabilitiescurrent": 636831,
    "convertiblenotespayablecurrent": 161736,
    "derivativeliabilities": 302156,
    "duetorelatedpartiescurrent": 123217,
    "liabilitiescurrent": 1223940,
    "liabilities": 1223940,
    "commonstockvalue": 104834,
    "additionalpaidincapital": 17774023,
    "retainedearningsaccumulateddeficit": -18351416,
    "stockholdersequity": -18351416,
    "liabilitiesandstockholdersequity": 751435,
    "preferredstockvalue": 54,
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": 500000000,
    "commonstocksharesissued": 26657443,
    "commonstocksharesoutstanding": 104834083,
    "preferredstockparorstatedvaluepershare": 0.001,
    "preferredstocksharesauthorized": 50000000,
    "preferredstocksharesissued": 746000,
    "preferredstocksharesoutstanding": 54130,
    "revenues": 750000,
    "professionalfees": 23000,
    "generalandadministrativeexpense": 359259,
    "researchanddevelopmentexpense": 321938,
    "operatingincomeloss": -1400368,
    "interestincomeoperating": 5,
    "interestexpense": 269382,
    "paymentsoffinancingcosts": 19411,
    "gainslossesonextinguishmentofdebt": 151308,
    "otherexpenses": 369,
    "amortizationofdebtdiscountpremium": 67250,
    "changeinunrealizedgainlossonhedgediteminfairvaluehedge1": 646705,
    "othernonoperatingincomeexpense": 441601,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -958767,
    "netincomeloss": -958767,
    "earningspersharebasicanddiluted": -0.01,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 72342193,
    "sharesissued": 104834083,
    "commonstockissuedforserviceshares": 2422902,
    "stockissuedduringperiodvalueissuedforservices": 575412,
    "commonstockissuedtorelatedpartiesforserviceshares": 9372909,
    "commonstockissuedtorelatedpartiesforserviceamount": 575412,
    "stockissuedduringperiodsharesconversionofconvertiblesecurities": 26657443,
    "stockissuedduringperiodvalueconversionofconvertiblesecurities": 14275,
    "financingcost": 19412,
    "commonstockissuedforaccruedpayablesrelatedpartiesshares": 16931101,
    "commonstockissuedforaccruedpayablesrelatedpartiesamount": 1577471,
    "commonstockissuedforaccountspayableshares": 577287,
    "commonstockissuedforaccountspayableamount": 44801,
    "commonstockissuedforconvertibledebtshares": 3982179,
    "commonstockissuedforconvertibledebtamount": 199567,
    "stockissuedduringperiodsharesother": 640000,
    "stockissuedduringperiodvalueother": 640000,
    "preferredsharesissuedfornotespayableshares": 100000,
    "preferredsharesissuedfornotespayableamount": 100000,
    "deemeddividendfromdownroundamount": -555000,
    "stockgrantedduringperiodvaluesharebasedcompensation": 210440,
    "stockissuedduringperiodvaluesharebasedcompensationgross": 575412,
    "gainlossonforeigncurrencyfairvaluehedgederivatives": -646705,
    "debtconversionoriginaldebtamount1": 67250,
    "accountsreceivable": -750000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 230401,
    "increasedecreaseinduetorelatedparties": 417081,
    "netcashprovidedbyusedinoperatingactivities": -986784,
    "proceedsfromconvertibledebt": 295000,
    "proceedsfromnotespayable": 50000,
    "proceedsfromissuanceofpreferredstockandpreferencestock": 640000,
    "netcashprovidedbyusedinfinancingactivities": 985000,
    "cashandcashequivalentsperiodincreasedecrease": -1784,
    "issuanceofstockandwarrantsforservicesorclaims": 1577471,
    "commonstockissuedforretiringpreferredshares": 14275,
    "preferredsharesissuedfornotespayable": 100000,
    "commonstockissuedforconvertibledebt": 199567,
    "commonstockissuedforaccountspayable": 44801,
    "derivativefairvalueofderivativeliability": 302156,
    "changeinfairvalueatinitialissuance": 544592,
    "changeinfairvalueduetoconversionofdebt": -199567,
    "changeinfairvalueofthederivative": -646705,
    "expectedvolatility": 2.06,
    "derivativefixedinterestrate": 0.018,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P2M30D",
    "workingcapitaldeficit": -472505,
    "fiscalyearannualizedcompensationbeingpaid": 140000,
    "nondilutivesharespercentage": 0.06,
    "initialshareawardsundercontracts": 617346,
    "additionalsharesearnedtomaintainownershippercentage": 1267553,
    "totalsharesearned": 1884899,
    "accruedcompensationamount": 23333,
    "officersanddirectorsemploymentagreementtermsdescription": "The Company entered five-year employment contracts with three of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares, so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company. ",
    "bonusamount": 170000,
    "accruedconsultingfees": 75000,
    "accruedbonusescurrent": 70000,
    "cashpaid": 308833,
    "accruedcompensation": 70000,
    "stockissuedduringperiodsharesissuedforservices": 9372909,
    "debtconversionconvertedinstrumentsharesissued1": 1968363,
    "debtconversionconvertedinstrumentamount1": 199567,
    "repaidamount": 30910,
    "accountspayableothercurrent": 14000,
    "advancefromrelatedparty": 26418,
    "paymentsforadvancetoaffiliate": 7000,
    "balancedue": 17384,
    "commonstockpaidamount": 60000,
    "definedbenefitplansettlementsbenefitobligation": 44801,
    "conversionofstockamountconverted1": 199567,
    "conversionofstocksharesconverted1": 3982179,
    "convertiblepreferredstocksharesissueduponconversion": 54130,
    "commonsharesissuedforsettlementofaccountspayable": 577287,
    "commonstocksharesissuedforcompensationvalue": 1577471,
    "commonstocksharesissuedforcompensationshares": 16931101,
    "interestpayablecurrent": 14013,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 3700000,
    "preferredstockissuedforcashshares": 640000,
    "debtcurrent": 100000,
    "convertibledescription": "The stock is convertible into common stock at 10 cents per share or 50% of the lowest trading price, whichever is lower 5 days prior to conversion. The Company has the right to convert the shares nine months after the issuance. The warrants are convertible at $0.15 per share within two years of issuance.",
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsbeginning": 1405000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsending": 1405000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepricebeginning3": 0.34,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsweightedaverageexercisepriceending": 0.34,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P5Y9M18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermending": "P4Y9M18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingnumberbeginning": 1405000,
    "sharebasedcompensationarrangementoutstandingnumberending": 1405000,
    "vestpercentageatgrant": 0.2,
    "commonstockexercisableterm": "P10Y",
    "optionsvesteddescription": "The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted. ",
    "investmentoptionsexerciseprice": 0.25,
    "numberofinstallmentsvest": 5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsgranted": 30000,
    "noncashorpartnoncashacquisitionnoncashfinancialorequityinstrumentconsiderationoptionsissued1": 40000,
    "fairvalueofoption": 9991,
    "sharebasedcompensationarrangementgrantsinperiodgross": 3700000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingnumberending1": 3700000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice1": 0.15,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepriceending1": 0.15,
    "weightedaverageremainingcontractlifegrantedone": "P2Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermending1": "P1Y4M6D",
    "deemeddividendfromdownround": 555000,
    "exercisepriceorwarrants": 0.15,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 3.125,
    "discountrate": 0.0014,
    "warrantsexcisableperiod": "P2Y",
    "fairvalueofwarrants": 303000,
    "warrantsgranted": 3700000,
    "fairvalueadjustmentofwarrants": 437000,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 0.15,
    "warrantsdescriptions": "the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares. ",
    "proceedsfromexerciseofwarrants": 349605,
    "deferredtaxassetsoperatinglosscarryforwards": 172915,
    "deferredtaxassetsvaluationallowance": 172915,
    "operatinglosscarryforwards": 11466695,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "debtinstrumentfaceamount": 11250,
    "agreementdescription": "Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company will receive $750,000 upon the enrollment of the 12th patient or the dosage level of 8.0 mg/kg, whichever is achieved first. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin",
    "issuanceoflicenseagreement": 5000000,
    "royaltyrate": 0.09,
    "netsales": "P20Y"
  },
  {
    "date": "2020-03-30",
    "symbol": "NBIO",
    "period": "FY",
    "entityregistrantname": "Nascent Biotech Inc.",
    "entitycentralindexkey": 1622057,
    "documenttype": "10-K",
    "amendmentflag": "false",
    "entityvoluntaryfilers": "No",
    "currentfiscalyearenddate": "--03-31",
    "entitywellknownseasonedissuer": "No",
    "entitysmallbusiness": "true",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entitycurrentreportingstatus": "Yes",
    "documentperiodenddate": "2020-03-31",
    "entityfilercategory": "Non-accelerated Filer",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2020,
    "entityextransitionperiod": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityinteractivedatacurrent": "Yes",
    "cashandcashequivalentsatcarryingvalue": 3218,
    "assetscurrent": 3218,
    "assets": 3218,
    "accountspayablecurrent": 852664,
    "convertiblenotespayablecurrent": -60000,
    "derivativeliabilities": 603836,
    "notespayablecurrent": 50000,
    "duetorelatedpartiescurrent": 21876,
    "liabilitiescurrent": 2878922,
    "liabilities": 2878922,
    "preferredstockvalue": 60,
    "commonstockvalue": 44890,
    "additionalpaidincapital": 13916995,
    "retainedearningsaccumulateddeficit": -16837649,
    "stockholdersequity": -16837649,
    "liabilitiesandstockholdersequity": 3218,
    "preferredstockparorstatedvaluepershare": 0.001,
    "preferredstocksharesauthorized": 10000000,
    "seriesapreferredstocksharesauthorized": 60000,
    "commonstockparorstatedvaluepershare": 0.17,
    "commonstocksharesauthorized": 100000000,
    "commonstocksharesissued": 44890262,
    "commonstocksharesoutstanding": 44890262,
    "professionalfees": 25000,
    "generalandadministrativeexpense": 320930,
    "researchanddevelopmentexpense": 293709,
    "operatingincomeloss": -3447311,
    "noninterestexpense": 6,
    "interestexpense": 86632,
    "derivativegainlossonderivativenet": 470216,
    "othernonoperatingincomeexpense": -556848,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -4004153,
    "netincomeloss": -4004153,
    "earningspersharebasicanddiluted": -0.12,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 34392716,
    "sharesissued": 44890262,
    "stockissuedduringperiodsharesnewissues": 1345422,
    "stockissuedduringperiodvaluenewissues": 176422,
    "commonstockissuedtorelatedpartiesforserviceshares": 1345522,
    "commonstockissuedtorelatedpartiesforserviceamount": 176422,
    "stockissuedduringperiodsharesstockoptionsexercised": 21427,
    "stockissuedduringperiodvaluestockoptionsexercised": 1071,
    "stockissuedduringperiodsharesissuedforservices": 6300000,
    "stockissuedduringperiodvalueissuedforservices": 927300,
    "commonstockissuedfortheconversionofpreferredsharesshares": 757,
    "commonstockissuedfortheconversionofpreferredshareamount": -707,
    "financingcost": 12500,
    "commonstockissuedaccruedpayablesrelatedpartyshares": 2469536,
    "commonstockissuedaccruedpayablesrelatedpartyamount": 293320,
    "preferredsharesissuedshares": 110000,
    "preferredsharesissuedamount": 110000,
    "sharebasedcompensation": 927300,
    "dividendssharebasedcompensationstock": 176422,
    "debtconversionoriginaldebtamount1": 61185,
    "deferredfinancecostsownsharelendingarrangementissuancecostsamortizationexpense1": -1250,
    "increasedecreaseinaccountspayableandaccruedliabilities": 327028,
    "increasedecreaseinduetorelatedparties": 1488927,
    "netcashprovidedbyusedinoperatingactivities": -554325,
    "proceedsfromissuanceofcommonstock": 115000,
    "proceedsfromconvertibledebt": 150000,
    "proceedsfromnotespayable": 50000,
    "proceedsfromissuanceofpreferredstockandpreferencestock": 110000,
    "proceedsfromissuanceofwarrants": 1071,
    "netcashprovidedbyusedinfinancingactivities": 426071,
    "cashandcashequivalentsperiodincreasedecrease": -128254,
    "issuanceofstockandwarrantsforservicesorclaims": 282000,
    "commonstockissuedrorretiringpreferredshares": 757,
    "duefromrelatedpartiescurrent": 60000,
    "accountspayableandaccruedliabilitiescurrent": -19000,
    "liabilitiesnoncurrent": -19000,
    "additions": 133620,
    "fairvalueassetsmeasuredonrecurringbasischangeinunrealizedgainloss": 470216,
    "derivativefairvalueofderivativeliabilityending": 603836,
    "propertyplantandequipmentusefullife": "P5Y",
    "workingcapitaldeficit": -2875704,
    "initialshareawardsundercontracts": 617346,
    "additionalsharesearnedtomaintainownershippercentage": 733553,
    "totalsharesearned": 1350899,
    "annualcompensationpaidforfiscalyear": 84000,
    "annualcompensationpercontractforfiscalyear": 140000,
    "salescommissionsandfees": 570000,
    "costsandexpensesrelatedparty": 26226,
    "accruedprofessionalfees": 430000,
    "cash": 4250,
    "accruedfees": 151000,
    "deferredcompensationarrangementwithindividualsharesissued": 600418,
    "deferredcompensationarrangementwithindividualfairvalueofsharesissued": 130536,
    "accruedfeesandotherrevenuereceivable": 854926,
    "accruedfeesconvertedamount": 293320,
    "accruedfeesconvertedamountintoshares": 2469536,
    "proceedsfromrelatedpartydebt": 37620,
    "paymentsforadvancetoaffiliate": 33370,
    "conversionpricepershare": 0.1725,
    "officersanddirectorsemploymentagreementtermsdescription": "the Company entered into five year employment contracts with three of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares, so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company. ",
    "commonsharesissuedamount": 115000,
    "commonsharesissuedshares": 1350000,
    "commonstocksharesissuedforservices": 6300000,
    "commonstocksharesvalueforservices": 927300,
    "conversionofstocksharesissued1": 757142,
    "convertiblepreferredstocksharesissueduponconversion": 50000,
    "warrantsexercisedvalue": 1071,
    "auctionmarketpreferredsecuritiessharesredeemed": 50000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsbeginning": 1405000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptionsending": 1405000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepricebeginning3": 0.34,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsweightedaverageexercisepriceending": 0.34,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P6Y9M18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermending": "P5Y9M18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingnumberbeginning": 1397000,
    "sharebasedcompensationarrangementoutstandingnumberending": 1405000,
    "vestpercentageatgrant": 0.2,
    "commonstockexercisableterm": "P10Y",
    "optionsvesteddescription": "The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted. ",
    "investmentoptionsexerciseprice": 0.25,
    "numberofinstallmentsvest": 5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsgranted": 30000,
    "noncashorpartnoncashacquisitionnoncashfinancialorequityinstrumentconsiderationoptionsissued1": 40000,
    "fairvalueofoption": 9991,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingbeginning": 237747,
    "sharebasedcompensationarrangementexpirationsinperiod": -216320,
    "stockissuedduringperiodexercised": -21427,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexercisepricebeginning": 0.2,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexpirationsinperiodweightedaverageexerciseprice1": 0.05,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice1": 0.05,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm1": "P2M30D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsaggregateintrinsicvalueoutstandingbeginning1": 18470,
    "exercisepriceorwarrants": 0.05,
    "warrantsexcisableperiod": "P1Y",
    "warrantsexercised": 21427,
    "warrantsissuedshares": 237747,
    "commonsharesissueduponexerciseofwarrants": 21427,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 216320,
    "proceedsfromexerciseofwarrants": 1071,
    "deferredtaxassetsoperatinglosscarryforwards": 2371694,
    "deferredtaxassetsvaluationallowance": -2371694,
    "operatinglosscarryforwards": -11293780,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "fairvalueofderivativeliability": 603836,
    "debtdiscountrelatedtonewdebt": 133620,
    "changeinfairvalueofthederivative": 470216,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.018,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P2M30D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 2.14,
    "accruedofmaintenancefees": 100000,
    "interestpaid": 28000,
    "totalaccruedmaintenancefees": 128000
  }
]